Navigation Links
Amylin Issues Statement in Response to Carl Icahn
Date:4/23/2009

SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today issued the following statement from James N. Wilson, Lead Independent Director, on behalf of the Amylin Board of Directors:

The Amylin Board of Directors welcomes continued three-way dialogue with Carl Icahn and Eastbourne Capital Management, L.L.C. to find a path to end a proxy contest. We hope that we can reach a resolution that will be in the best interests of all Amylin shareholders.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

This press release may be deemed to be solicitation material in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Amylin has filed the definitive proxy statement with the Securities and Exchange Commission ("SEC") on April 20, 2009. INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE BLUE PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and securityholders may obtain the proxy statement and other relevant documents free of charge at the SEC's Web site, www.sec.gov or from Amylin Investor Relations at 9360 Towne Centre Drive, San Diego, California 92121.

PARTICIPANTS IN SOLICITATION

Amylin and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Information regarding the interests of Amylin's directors and executive officers in the proxy contest are included in Amylin's definitive proxy statement.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Icahn Asks Amylin to Allow Discussions With Eastbourne
2. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
3. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
4. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
5. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
6. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
7. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
8. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
9. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
10. Amylin Pharmaceuticals Reports Third Quarter Financial Results
11. Amylin Pharmaceuticals to Webcast Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... announced the formation of its Medical/Clinical Advisory Board. ... industry veterans who enhance the range and depth ... development of its novel prenatal diagnostic tests.  These ... and strategic guidance for the company,s product development ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, is ... fully 21 CFR Part 11-compliant email client designed to provide product vigilance departments ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical ... update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data ... the existing policy. AMIA recommended that NIH earmark funding for researchers to produce ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
Breaking Biology News(10 mins):